E-4031
目录号 : GC13490An antiarrhythmic, ERG potassium channel blocker
Cas No.:113558-89-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 7.7 nM for hERG
E-4031 is an antiarrhythmic agent blocking the ATP-sensitive potassium channel.
ATP-sensitive potassium channels are distributed in tissues widely including muscle, pancreatic beta cells and brain. Their activity is regulated by adenine nucleotides, being activated by falling ATP and rising ADP levels. Thus, ATP-sensitive potassium channels link cellular metabolism with membrane excitability.
In vitro: It has been reported that E-4031 could induce EADs or TdP, and such induction correlated with a significant increase in variability of repolarization. In addition, E-4031 at 0.1 uM was able to significantly prolong cycle length, action potential duration, and depolarized maximum diastolic potential. E-4031could also reduce the upstroke velocity of the action potential as well as the diastolic depolarization rate [1].
In vivo: Animal study showed that E-4031 at 0.01 and 0.1 mg/kg could provide effective in-vitro plasma concentrations to significantly inhibit Ikr and thus delayed the repolarization beyond the initiation of diastole, leading to the inversion of electro-mechanical coupling, which provides an ideal proarrhythmic substrate [2]. Another sutdy found that E-4031 could prolong QT interval and ARI in all LV layers, though the magnitude of prolongation was greatest in Mid, particularly during bradycardia [3].
Clinical trial: Up to now, E-4031 is still in the preclinical development stage.
References:
[1]. Verheijck EE, et al. Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. Circ Res. 1995 Apr;76(4):607-15.
[2]. Izumi-Nakaseko H, et al. Effects of selective IKr channel blockade by E-4031 on ventricular electro-mechanical relationship in the halothane-anesthetized dogs. Eur J Pharmacol. 2014 Oct 5;740:263-70.
[3]. Izumi D, et al. Effects of bepridil versus E-4031 on transmural ventricular repolarization and inducibility of ventricular tachyarrhythmias in the dog. Pacing Clin Electrophysiol. 2010 Aug;33(8):950-9.
| Cas No. | 113558-89-7 | SDF | |
| 化学名 | N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide | ||
| Canonical SMILES | CC1=NC(CCN2CCC(C(C3=CC=C(NS(C)(=O)=O)C=C3)=O)CC2)=CC=C1 | ||
| 分子式 | C21H27N3O3S | 分子量 | 401.52 |
| 溶解度 | 25mg/mL in DMSO, 0.3mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4905 mL | 12.4527 mL | 24.9054 mL |
| 5 mM | 0.4981 mL | 2.4905 mL | 4.9811 mL |
| 10 mM | 0.2491 mL | 1.2453 mL | 2.4905 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet